Furthermore, the therapeutic efficacy of an MV vector expressing a single-chain antibody (sc-Fv) specific for the extracellular domain of the prostate-specific membrane antigen (PSMA) was evaluated in mice carrying LNCaP and PC3-PSMA prostate tumors [61]. This evidence concerns the gene FOLH1 and prostate neoplasm.